Study of the Exogenous Peptide Effect on the TGF-β1 Expression-A Risk Factor for the Hepatocellular Carcinoma

摘要

An article deals with the influence of the transforming growth factor beta-1 (TGF-β1) on the carcinogenesis of hepatic cells, as well as attention is given to the role of this factor in the hepatocellular carcinoma (HCC) progression. We monitored two groups of patients: in the treatment group, patients were administered cancer vaccine therapy and anti-relapse immune corrector Arecur-a complex of exogenous peptides with anti-inflammatory, anti-infective and regenerating properties; in the reference group, patients were not administered immune corrector. The study showed that the cancer vaccine has a positive effect on the activity of T-cell immunity and interleukin-2 expression level. The result of the inclusion of anti-relapse immune corrector Arecur in the patients' management regimen was the reduction of TGF-β1 expression. The lower recurrence rate of HCC in the treatment group suggests that Arecur may prevent possible recurrences and metastasis of HCC by limiting TGF-β1 expression. Future researches of anti-relapse immune correction regimens for patients with hepatic tumours may improve the therapeutic strategy and prevention of the disease progression in the long term. In addition, immune correction using exogenous peptides is likely capable of preventing the malignancy in patients with chronic hepatitis and liver cirrhosis.